Mission Statement

NTAP’s mission, “Accelerating the development of effective therapeutics for plexiform and cutaneous neurofibromas” is achieved via four mechanisms:

1) Focusing on Therapeutics

We are vigilant about advancing the most promising ideas for plexiform and cutaneous neurofibroma therapeutics. The pathway from the lab (where researchers are making discoveries) to the clinic (where therapies are needed) is often lengthy and convoluted. NTAP facilitates the timely translation of innovative discoveries into treatments for plexiform and cutaneous neurofibromas.

2) Fostering Collaboration

NTAP recognizes that developing treatments requires collaboration. We foster relationships across a broad research community including the pharmaceutical industry, regulatory agencies, private foundations and academic centers to increase the pace at which promising research can be converted into patient therapies. Advisory boards with diverse membership ensure that NTAP complements the ongoing efforts of the greater neurofibromatosis research community.

3) Open and Timely Sharing of Results

We require that data from funded projects be shared openly in real time. The NTAP leadership facilitates communication among collaborators and enables dissemination of data appropriately. In addition, research progress is monitored closely by the NTAP directors and the scientific advisory board to ensure that projects with the most potential for translational success are advanced.

4) Streamlining the Research Process

We work hard to identify critical gaps in knowledge that limit the development of therapeutics for plexiform and cutaneous neurofibromas and then recruit scientists with innovative ideas to address these gaps. The grants process is targeted to specific research questions and designed to provide quick feedback and funding. NTAP is poised to provide funding and other resources to investigators, allowing basic science discoveries to be aggressively translated into therapeutics for plexiform and cutaneous neurofibromas.